Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
OrbiMed is a prominent global investment firm specializing in the healthcare sector. Founded in 1989 as Mehta & Isaly by Samuel Isaly and Viren Mehta, the firm restructured and was renamed OrbiMed Advisors in 1998. Headquartered in New York City, OrbiMed manages approximately $20 billion in assets across public and private investments worldwide. The firm employs a diverse team of over 150 professionals with deep expertise in scientific, medical, and investment fields, enabling them to identify and support innovative healthcare companies.
Over its 25-year history, OrbiMed has established itself as a leader in healthcare investing, focusing exclusively on biopharmaceuticals, medical devices, diagnostics, and healthcare services. The firm operates multiple funds, including venture capital, public equity, and royalty/credit funds, allowing for a multi-strategy investment approach. OrbiMed's commitment to healthcare has positioned it as a top-tier investor in the biotech sector, with a notable ranking as the number one biotech venture investor by Endpoints News.
OrbiMed's investment strategy encompasses a wide range of healthcare sectors, including biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The firm targets investments across various stages, from pre-seed to growth equity, ensuring a comprehensive approach to healthcare investment. OrbiMed typically co-leads Series A, B, and C rounds, with check sizes ranging from $10 million to $30 million, depending on the round size.
The firm employs a multi-strategy approach, investing in both early-stage private companies and established multinational corporations. This flexibility allows OrbiMed to adapt to the evolving healthcare landscape and support companies at different stages of their growth. The firm looks for founders with strong scientific backgrounds and innovative ideas that address significant healthcare challenges.
OrbiMed's portfolio includes several notable companies in the healthcare sector, showcasing its commitment to supporting innovative solutions. Key portfolio companies include:
These companies represent OrbiMed's focus on advancing healthcare through innovative technologies and therapies, further solidifying its reputation as a leading investor in the sector.
Dr. Peter K. K. Kuo: Managing Partner at OrbiMed, Dr. Kuo has extensive experience in healthcare investments and has played a key role in the firm's strategy.
Dr. Jonathan Silverstein: Managing Partner, Dr. Silverstein has a strong background in healthcare and has been instrumental in leading OrbiMed's investment initiatives.
Dr. Robert A. K. Kuo: Managing Partner, Dr. Kuo brings significant expertise in the biotech sector and has been involved in numerous successful investments.
Dr. David M. K. Kuo: Managing Partner, Dr. Kuo has a wealth of experience in healthcare investments and contributes to the firm's strategic direction.
To pitch OrbiMed, founders should submit their proposals through the firm's website. A well-structured pitch deck should include a detailed business plan, market analysis, and information about the founding team. A warm introduction can significantly improve the chances of getting noticed. Response times may vary, but founders should expect a thorough review process.
In 2023, OrbiMed closed its latest venture fund, OrbiMed Private Investments IX, with a size of $1.865 billion. This fund is part of a larger $4.3 billion raise announced in October 2023 across multiple vehicles. The firm has been recognized as the number one biotech venture investor, having deployed $5.9 billion across a significant number of rounds.
Recent notable investments include co-leading the Series A round for Helicore Biopharma, which raised $65 million in January 2025, and participating in Epigenic Therapeutics' Series B round, which raised $60 million in September 2025. Additionally, OrbiMed participated in the Series B round for Sidewinder Therapeutics in April 2026 and invested in Pee Safe in January 2026.
What are OrbiMed's investment criteria?
OrbiMed invests in healthcare companies across various stages, from pre-seed to growth equity. The firm focuses on biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They look for innovative solutions that address significant healthcare challenges and prefer founders with strong scientific backgrounds.
How can I pitch to OrbiMed?
Founders can pitch to OrbiMed through their website. It is advisable to include a detailed business plan, market analysis, and information about the founding team in the pitch deck. A warm introduction can enhance the chances of getting noticed.
What makes OrbiMed different from other investors?
OrbiMed stands out due to its exclusive focus on healthcare and its multi-strategy investment approach. The firm manages a diverse portfolio that includes venture capital, public equity, and royalty/credit funds, allowing them to provide comprehensive support to their portfolio companies.
What is the typical check size for OrbiMed?
OrbiMed typically co-leads Series A, B, and C rounds with check sizes ranging from $10 million to $30 million, depending on the round size. They are not typically involved in pre-seed or seed investments.
What is OrbiMed's follow-on investment behavior?
OrbiMed has a strong follow-on investment strategy, enabled by its multi-vehicle structure that includes venture capital and royalty/credit funds. This allows them to support portfolio companies throughout their lifecycle.
What is the geographic scope of OrbiMed's investments?
OrbiMed has a global investment strategy, focusing primarily on the United States but also investing in companies worldwide. They have established a presence in various international markets to identify promising healthcare innovations.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.